Physician profile
Subhasish Bose
NPI 1770816118
$2,224.61
in general payments reported to CMS, 2019-2025
12 companies · $616 in 2025
The $616 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $562 · 2021: $160 · 2022: $431 · 2024: $127 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $453 · Consulting Fee: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $453.25 |
| Consulting Fee | $290.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| C. R. Bard, INC. & Subsidiaries | $500.00 | 2020 | |
| Radiometer America, INC | $290.00 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $271.87 | 2019-2022 | |
| Amgen INC. | $208.81 | 2022 | |
| Novo Nordisk INC | $184.61 | 2025 | Wegovy, Ozempic |
| Vifor Pharma, INC. | $177.14 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $149.94 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $123.38 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $119.98 | 2025 | Terlivaz |
| Calliditas Therapeutics US INC. | $109.72 | 2024 | |
| Aurinia Pharma U.S., INC. | $72.71 | 2022 | |
| Rockwell Medical, INC. | $16.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subhasish Bose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.